

## QIBA PET Amyloid Biomarker Committee

27 March 2015 at 9:00 AM CT (GMT-6)

### Call Summary

#### In attendance:

##### Co-chairs:

Satoshi Minoshima, MD, PhD  
Eric Perlman, MD  
Anne Smith, PhD

##### Participants:

Orest Boyko, MD, PhD  
Santiago (Santi) Bullich, PhD  
Norman Foster, MD  
John Hoffman, MD  
Gregory Klein, PhD  
Nancy Obuchowski, PhD

##### RSNA:

Joe Koudelik  
Julie Lisiecki

#### General Discussion:

- Updates were provided by two task force leaders:
  - Dr. Subramaniam (Claims/ Test-Retest) and
  - Dr. Klein (Site validation)
- Dr. Subramaniam discussed progress on the Claims (test-retest / meta-analysis) literature analysis.
  - Remaining questions:
    - What is the primary goal for the test-retest study?
    - What is the best time interval for obtaining test-retest data?
    - Does the time interval between base-line and follow up scan make a difference?
    - Can aggregate data stand alone?
  - Feedback from the BC is encouraged
    - Dr. Subramaniam to provide a cover email to accompany his spreadsheet with a request to the QIBA PET Amyloid BC re: the test-retest study
  - Another task force was suggested to work on F<sup>18</sup> analysis to feed the Profile
- Dr. Klein discussed Profile recommendations for Sections 3.6.4 (Phantom Imaging) and 3.6.6 (Quality Control: Interpretation):
  - Consideration being given to revising section 3.6.4
    - Two levels/uses of physical phantom imaging will be included for the Profile:
      1. Initial scanner assessment to include Hoffman phantom (also to be performed after major hardware or software upgrade)
      2. Maintenance follow-up phantom imaging not requiring Hoffman phantom
- Use of either the Hoffman DRO, or an FDG\_PET DRO, with recommendations for image reconstruction, was also discussed
  - The DRO would be needed in addition to the physical phantom
- Concerns discussed regarding the physical phantoms:
  - Currently, only 50% of sites have either a Jaszczak or NEMA phantom
  - It is estimated that only about 5% of sites have the Hoffman DRO
    - However, everyone has a uniformity phantom, which could be tested more frequently

#### Action items:

- Dr. Subramaniam to provide cover email text for RSNA Staff to distribute his spreadsheet to the Amyloid BC for the test-retest study feedback
- Dr. Klein to update the Profile based on feedback from the call

#### Proposed Nuclear Medicine Calendar for April (Fridays, 9 am CT):

- **April 3** – FDG-PET Biomarker Ctte
- **April 10** – PET Amyloid Biomarker Ctte
- **April 17** – (proposed) SPECT Biomarker Ctte
- **April 24** – PET Amyloid Biomarker Ctte